Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia
March 20, 2017
???Both the extent and durability of responses in these relapsed and refractory CLL patients treated with CAL-101 are very promising,??? said Dr. Albert Yu, M.D., Chief Medical Officer, Calistoga Pharmaceuticals. ???We continue to enroll patients and the results of this study will help us select an optimal biologic dose for future studies.???
These interim results are part of a cohort expansion of the ongoing Phase 1 trial of CAL-101, which is enrolling patients with relapsed or refractory CLL, indolent non-Hodgkin??™s lymphoma (NHL), aggressive NHL, acute myeloid leukemia (AML), and multiple myeloma (MM). Clinical response data evaluating at least 90 patients is expected to be available by the end of 2009.
???These encouraging results support future evaluation of CAL-101 in CLL patients both as a single agent and in combination with standard regimens,??? noted Carol G. Gallagher, Pharm. D., Chief Executive Officer of Calistoga Pharmaceuticals. ???We anticipate starting Phase 2/3 clinical studies in 2010.???
Source Calistoga Pharmaceuticals